Combination Therapy and Long-Term Safety Quiz
10 Questions
1 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

Which molecule represents 44% market share in the 1st year with 2,156 units and grew by 487%?

  • Bosentor
  • Macimit
  • Opsumit
  • Maacy (correct)
  • Which molecule is represented by 1,621 units, lost market share by 19%, and declined by -35% YOY 2022?

  • Tracleer
  • Macitentan
  • Bosentor
  • Bosentan (correct)
  • Which molecule is represented by 826 units, gained 10% market share, and grew by 1,696%?

  • Ambrisentan (correct)
  • Volibris
  • Bosentor
  • Tracleer
  • Which molecule represents 67% market share and is growing vs the decline of Bosentan?

    <p>Macitentan</p> Signup and view all the answers

    Which product significantly reduced the risk of the first morbidity and mortality event by 45%?

    <p>Macitentan</p> Signup and view all the answers

    Which product offers an average 5.9 years of survival in combination therapy?

    <p>Macitentan</p> Signup and view all the answers

    Which product had patients on 10mg with a greater chance to improve FC Status by 74%?

    <p>Macitentan</p> Signup and view all the answers

    Which product significantly increased the 6-minute walk distance by 22 meters?

    <p>Macitentan</p> Signup and view all the answers

    Which product significantly reduced death due to PAH or hospitalization by 45%?

    <p>Macitentan</p> Signup and view all the answers

    Which product had patients receiving the 10mg combination therapy with a reduction in the risk of being hospitalized for PAH of 37.4%?

    <p>Macitentan</p> Signup and view all the answers

    More Like This

    Macy's Expansion in the Roaring Twenties
    5 questions
    Macy's Thanksgiving Day Parade Quiz
    5 questions
    Macy's Thanksgiving Day Parade Quiz
    7 questions
    Use Quizgecko on...
    Browser
    Browser